Research progress in pathogenesis of stroke-related sarcopenia

WANG Lijing; ZHAN Qing

doi:10.12022/jnnr.2016-0045

PDF(1463 KB)

Journal of Neurology and Neurorehabilitation ›› 2016, Vol. 12 ›› Issue (2) : 102-105. DOI: 10.12022/jnnr.2016-0045

Review

Research progress in pathogenesis of stroke-related sarcopenia

WANG Lijing^{1, 2}, ZHAN Qing^{1, 2}

Author information +

History +

Abstract

Physical disability is common in stroke survivors. Sarcopenia after stroke has a strong impact on the decision and efficiency of rehabilitation and it may lead to the delayed recovery of patients. The pathogenesis of sarcopenia has not been investigated in details. “Stroke-related sarcopenia” was proposed in 2013 and several factors have been well known to contribute to sarcopenia, such as immobilization, impaired feeding and the activation of ubiquitin proteasome pathway. This paper reviews the recent studies on pathogenesis of stroke-related sarcopenia and distinguishes it from sarcopenia induced by other diseases, providing a basis for the prevention and therapy of sarcopenia after stroke.

Key words

Stroke / Muscular atrophy / Pathogenesis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Lijing, ZHAN Qing. Research progress in pathogenesis of stroke-related sarcopenia[J]. Journal of Neurology and Neurorehabilitation. 2016, 12(2): 102-105 https://doi.org/10.12022/jnnr.2016-0045

References

[1] GO A S, MOZAFFARIAN D, ROGER V L, et al. Heart disease and stroke statistics_2013 update: a report from the American Heart Association[J]. Circulation, 2013, 127(1):e6-e245.
[2] SCHERBAKOV N, DOEHNER W. Sarcopenia in stroke-facts and numbers on muscles loss accounting for disability after stroke[J]. J Cachexia Sarcopnenia Muscle, 2011, 2(1):5-8.
[3] CARDA S, CISARI C, INVERNIZZI M. Sarcopenia or muscle modifications in neurologic disease: a lexical or pathophysiological difference?[J]. Eur J Phys Rehabil Med, 2013, 49(1):119-130.
[4] ARASAKI K, IGARASHI O, ICHIKAWA Y, et al. Reduction in the motor unit number estimate (MUNE) after cerebral infarction[J]. J Neurol Sci, 2006, 250(1-2):27-32.
[5] LI X, SHIN H, ZHOU P, et al. Power spectral analysis of surface electromyography (EMG) at matched contraction levels of the first dorsal interosseous muscle in stroke survivors[J]. Clin Neurophysiol, 2014, 125(5):988-994.
[6] HARRIS M L, POLKEY M I, BATH P M, et al. Quadriceps muscle weakness following acute hemiplegic stroke[J]. Clin Rehabil, 2001, 15(3):274-281.
[7] KOSTKA T. Quadriceps maximal power and optimal shortening velocity in 335 men aged 23-88 years[J]. Eur J Appl Physiol, 2005,95(2-3):140-145.
[8] DE DEYNE P G, HAFER-MACKO C E, IVEY F M, et al. Muscle molecular phenotype after stroke is associated with gait speed[J]. Muscle Nerve, 2004, 30(2):209-215.
[9] SCHERBAKOV N, VON HAEHLING S, ANKER S D, et al. Stroke induced Sarcopenia: muscle wasting and siability after stroke[J]. Int J Cardiol, 2013, 170(2):89-94.
[10] SCHERBAKOV N, SANDEK A, DOEHNER W. Stroke-related Sarcopenia: specific characteristics[J]. J Am Med Dir Assoc, 2015, 16(4):272-276.
[11] KORTEBEIN P, FERRANDO A, LOMBEIDA J, et al. Effect of 10 days of bed rest on skeletal muscle in healthy older adults[J]. JAMA, 2007, 297(16):1772-1774.
[12] CARIN-LEVY G, GREIG C, YOUNG A, et al. Longitudinal changes in muscle strength and mass after acute stroke[J]. Cerebrovasc Dis, 2006, 21(3):201-207.
[13] JØRGENSEN L, JACOBSEN B K. Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1 year prospective study[J]. Bone, 2001, 28(6):655-659.
[14] HUGHES V A, FRONTERA W R, ROUBENOFF R, et al. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity[J]. Am J Clin Nutr, 2002, 76(2):473-481.
[15] RYAN A S, BUSCEMI A, FORRESTER L, et al. Atrophy and intramuscular fat in specific muslces of the thigh: associated weakness and hyperinsulinemia in stroke survirors[J]. Neurorehabil Neural Repair, 2011, 25(9):865-872.
[16] MCPHERRON A C, LAWLER A M, LEE S J. Regulation of skeletal muscle mass in mice by a new TGFbeta superfamily member[J]. Nature, 1997, 387(6628):83-90.
[17] MENDIAS C L, GUMUCIO J P, DAVIS M E, et al. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis[J]. Muscle Nerve, 2012, 45(1):55-59.
[18] RYAN A S, IVEY F M, PRIOR S, et al. Skeletal muscle hypertrophy and muscle myostatin reduction after resistive training in stroke survivors[J]. Stroke, 2011, 42(2):416-420.
[19] SPRINGER J, SCHUST S, PESKE K, et al. Catabolic signaling and muscle wasting after acute ischemic stroke in mice[J]. Stroke, 2014, 45(12):3675-3683.
[20] BODINE S C, LATRES E, BAUMHUETER S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy[J]. Science, 2001, 294(5547):1704-1708.
[21] SACHECK J M, HYATT J P, RAFFAELLO A, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases[J]. FASEB J, 2007, 21(1):140-155.
[22] HETTWER S, DAHINDEN P, KUCSERA S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients[J]. Exp Gerontol, 2013, 48(1):69-75.
[23] BEZAKOVA G, RUEGG M A. New insights into the roles of agrin[J]. Nat Rev Mol Cell Biol, 2003, 4(4):295-308.
[24] DREY M, SIEBER C C, BAUER J M, et al. C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction[J]. Exp Gerontol, 2013, 48(1):76-80.
[25] SCHERBAKOV N, KNOPS M, EBNER N, et al. Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation[J]. J Cachexia Sarcopenia Muscle, 2016, 7(1):60-67.

Funding

Foundation of Shanghai Disabled Persons' Federation (No. K2014015); Shanghai Three-year Action Planning for Further Accelerating Development of Chinese Medicine (No. ZY3-FWMS-2-1012); “New Star” Project of Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine (No. XX2016-03)